CJC-1295 No DAC & Ipamorelin

Ipamorelin / CJC-1295 (No DAC) Overview

The combined formulation of Ipamorelin and CJC-1295 (No DAC) represents a pinnacle in secretagogue research, offering a dual-pathway approach to optimizing growth hormone (GH) levels. This blend is specifically designed for researchers seeking to observe the physiological benefits of GH elevation—such as enhanced tissue repair and metabolic efficiency—while preserving the natural pulsatile release rhythm of the endocrine system.

Ipamorelin is a selective ghrelin receptor agonist known for its precision. Unlike earlier generation peptides, it does not stimulate the release of cortisol or prolactin, making it an ideal candidate for long-term study. Its primary metabolic roles include the promotion of fat oxidation and the support of bone mineral density through the activation of the ghrelin/growth hormone secretagogue receptor.

CJC-1295 (No DAC) functions as a GHRH (Growth Hormone Releasing Hormone) analog. It extends the half-life of natural GHRH, providing a sustained signal to the pituitary gland to increase GH production. When administered together, Ipamorelin acts as the "trigger" while CJC-1295 acts as the "amplifier," resulting in a total GH output that is significantly higher than the sum of their individual effects.

Product Structure

This product consists of two distinct peptide chains provided in a highly purified lyophilized form.

• Ipamorelin Molecular Formula: C38H49N9O5
• CJC-1295 Molecular Formula: C152H252N44O42
• Structure Solution Formula: Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) + CJC-1295 (Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Ile-Ser-Arg-NH2).

Research and Mechanism of Action

The mechanism of this blend is rooted in the "dual signaling" theory of the anterior pituitary. Research indicates that the combination facilitates a more robust anabolic environment by maximizing the peak of each growth hormone pulse.

Research Metric

Ipamorelin Observation

CJC-1295 Observation

Pulsatile Pattern

Maintains natural frequency

Enhances pulse amplitude

Muscle Synthesis

Accelerates fiber repair

Promotes lean mass accretion

Digestive Health

Gastric motility support

Metabolic rate optimization

Glucocorticoids

Counteracts bone loss

Improves insulin sensitivity

The synergy allows for the elevation of baseline GH levels (via Ipamorelin) while CJC-1295 ensures that the "spikes" in GH are more pronounced, leading to superior results in skeletal health, muscle development, and overall metabolic performance.

Storage and Handling

Peptides are highly sensitive to environmental factors. Proper storage is essential to maintain biological activity.

• Lyophilized Powder: Store at -20 degrees Celsius for long-term stability (up to 2 years).
• Reconstituted Solution: Must be stored at 2 to 8 degrees Celsius (refrigerated).
• Handling: Avoid excessive agitation or shaking of the vial, as this can break the delicate peptide bonds. Protect from direct ultraviolet light exposure.

About The Author

The preceding scientific literature underwent research, editing, and compilation by Dr. E. Logan, M.D. Dr. E. Logan earned a medical doctorate from Case Western Reserve University School of Medicine and possesses a Bachelor of Science degree in molecular biology.

Scientific Journal Author

Dr. Dominique Bridon is a PhD in Organic Chemistry and a Master of Chemical Engineering. His career has been dedicated to peptide research and the development of long-lasting analogs. He has held executive roles at organizations such as Conjuchem and Abbott Laboratories and has worked under Nobel Laureate Sir Derek H. R. Barton.

Dr. Dominique Bridon is cited here as a prominent researcher in CJC-1295 development. This reference does not constitute an endorsement or recommendation by this scientist for purchasing, selling, or using this product. No relationship exists between the supplier and this doctor.

Resources

1 K. Raun et al., "Ipamorelin, the first selective growth hormone secretagogue," Eur. J. Endocrinol., vol. 139, no. 5, pp. 552-561, Nov. 1998. [PubMed]

2 N. B. Andersen et al., "The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation in adult rats," Growth Horm. IGF Res., vol. 11, no. 5, pp. 266-272, Oct. 2001. [PubMed]1

3 J. Svensson et al., "The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats," J. Endocrinol., vol. 165, no. 3, pp. 569-577, Jun. 2000. [Pub2Med]

4 E. Adeghate and A. S. Ponery, "Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats," Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403-406, Dec. 2004. [PubMed]

5 D. E. Beck et al., "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus," Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527-1534, Dec. 2014. [PubMed]

6 B. Greenwood-Van Meerveld et al., "Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus," J. Exp. Pharmacol., vol. 4, pp. 149-165, Oct. 2012. [PubMed]

7 M. Alba et al., "Once-daily administration of CJC-1295... normalizes growth in the GHRH knockout mouse," Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006. [PubMed]

8 M. Ionescu and L. A. Frohman, "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295," J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792-4797, Dec. 2006. [PubMed]

9 M. C. Van Hout and E. Hearne, "Netnography of Female Use of the Synthetic Growth Hormone CJC-1295," Subst. Use Misuse, vol. 51, no. 1, pp. 73-84, Jan. 2016. [PubMed]

10 Jette, Lucie et al. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog. [Research Gate]